Echocardiography Clinical Trials
71 recruitingProcedure
Phase 122Phase 220Not Applicable3Phase 32Early Phase 11
Showing 1–20 of 71 trials
Recruiting
Phase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more
Fred Hutchinson Cancer Center54 enrolled1 locationNCT06013423
Recruiting
Phase 2
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaRichter Syndrome
Roswell Park Cancer Institute32 enrolled1 locationNCT06863402
Recruiting
Phase 1Phase 2
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma
OHSU Knight Cancer Institute40 enrolled1 locationNCT06249191
Recruiting
Phase 1
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Metastatic Malignant Solid Neoplasm
Fred Hutchinson Cancer Center24 enrolled1 locationNCT06043713
Recruiting
Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Early-stage HER2+ Breast Cancer
Alliance for Clinical Trials in Oncology1,524 enrolled671 locationsNCT06876714
Recruiting
Phase 1Phase 2
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Alliance for Clinical Trials in Oncology88 enrolled42 locationsNCT06232044
Recruiting
Phase 2
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+3 more
City of Hope Medical Center35 enrolled1 locationNCT06815003
Recruiting
Phase 1
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Recurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma
City of Hope Medical Center27 enrolled1 locationNCT06815029
Recruiting
Phase 1
Gilteritinib for the Treatment of ALK NSCLC
Stage IV Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma
University of Michigan Rogel Cancer Center30 enrolled3 locationsNCT06225427
Recruiting
Phase 2
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Ewing SarcomaBone SarcomaSynovial Sarcomas+7 more
Northwestern University73 enrolled1 locationNCT06571734
Recruiting
Phase 1
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Roswell Park Cancer Institute26 enrolled1 locationNCT06871410
Recruiting
Phase 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+15 more
Sumithira Vasu54 enrolled2 locationsNCT05418088
Recruiting
Prognostic Value of Right Ventricular-pulmonary Arterial Coupling Assessed by Echocardiography in Septic Patients
Sepsis
University Medical Center Ho Chi Minh City (UMC)215 enrolled1 locationNCT06887140
Recruiting
Phase 1
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Triple-Negative Breast Cancer
University of Southern California20 enrolled1 locationNCT05989828
Recruiting
Phase 1
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center15 enrolled1 locationNCT06287944
Recruiting
Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Study of Bronchiectasis and Associated Cardiovascular Comorbidities
Bronchiectasis
Assiut University30 enrolled1 locationNCT05783869
Recruiting
Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
AL Amyloidosis
SWOG Cancer Research Network338 enrolled117 locationsNCT06022939
Recruiting
Phase 1
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center33 enrolled1 locationNCT06195891
Recruiting
Early Phase 1
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
City of Hope Medical Center15 enrolled1 locationNCT06735690